Evidence map›Paper›PMID 41120271›Full record

ArticleBlood cancer journal2025

Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.

Nicholas J Short, Elias Jabbour, Walid Macaron, Nitin Jain, Fadi G Haddad, Sanam Loghavi, Tapan M Kadia, Partow Kebriaei, Eitan Kugler, Jairo Matthews and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nicholas J Short *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. nshort@mdanderson.org.ORCID 0000-0002-2983-2738
Elias Jabbour *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4465-6119
Walid Macaron *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fadi G HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9702-8485
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8980-3202
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9892-9832
Partow KebriaeiDepartment of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eitan KuglerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jairo MatthewsDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rebecca GarrisDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7621-377X
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1908-3307

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672UT | University of Texas MD Anderson Cancer Center (MD Anderson) CA016672
6 · The paper itself

Abstract

Baseline cytomolecular features and measurable residual disease (MRD) dynamics are both strongly prognostic in acute lymphoblastic leukemia (ALL). Whether early MRD response can overcome the adverse prognosis of high-risk (HR) cytomolecular features is largely unknown. We retrospectively identified 161 patients with newly diagnosed B-cell ALL who underwent MRD assessment with next-generation sequencing (NGS) for IG/TR rearrangements (sensitivity: 1 × 10

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAgedAged, 80 and overCyclophosphamideDexamethasoneDisease-Free SurvivalDoxorubicinFollow-Up StudiesHigh-Throughput Nucleotide SequencingHumansImmunotherapy, AdoptiveKaplan-Meier EstimateCyclophosphamideDexamethasoneDoxorubicinVincristine

Identifiers

PMID41120271
PMCPMC12540711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.